312 related articles for article (PubMed ID: 37006260)
21. From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies.
Fantini MC; Guadagni I
Dig Liver Dis; 2021 May; 53(5):558-565. PubMed ID: 33541800
[TBL] [Abstract][Full Text] [Related]
22. Loganin inhibits macrophage M1 polarization and modulates sirt1/NF-κB signaling pathway to attenuate ulcerative colitis.
Liu S; Shen H; Li J; Gong Y; Bao H; Zhang J; Hu L; Wang Z; Gong J
Bioengineered; 2020 Dec; 11(1):628-639. PubMed ID: 33034242
[TBL] [Abstract][Full Text] [Related]
23.
Sun J; Zhao P; Ding X; Li F; Jiang J; Huang H; Ji L
Mediators Inflamm; 2022; 2022():1108569. PubMed ID: 36619207
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic effects of dihydroartemisinin in multiple stages of colitis-associated colorectal cancer.
Bai B; Wu F; Ying K; Xu Y; Shan L; Lv Y; Gao X; Xu D; Lu J; Xie B
Theranostics; 2021; 11(13):6225-6239. PubMed ID: 33995655
[TBL] [Abstract][Full Text] [Related]
25. MK2: an unrecognized regulator of tumor promoting macrophages in colorectal cancer?
Castillo EF; Ray AL; Beswick EJ
Macrophage (Houst); 2016; 3():. PubMed ID: 26998523
[TBL] [Abstract][Full Text] [Related]
26. An ultralow dose of the NADPH oxidase inhibitor diphenyleneiodonium (DPI) is an economical and effective therapeutic agent for the treatment of colitis-associated colorectal cancer.
Kuai Y; Liu H; Liu D; Liu Y; Sun Y; Xie J; Sun J; Fang Y; Pan H; Han W
Theranostics; 2020; 10(15):6743-6757. PubMed ID: 32550901
[TBL] [Abstract][Full Text] [Related]
27. Cross-talk between Colon Cells and Macrophages Increases ST6GALNAC1 and MUC1-sTn Expression in Ulcerative Colitis and Colitis-Associated Colon Cancer.
Kvorjak M; Ahmed Y; Miller ML; Sriram R; Coronnello C; Hashash JG; Hartman DJ; Telmer CA; Miskov-Zivanov N; Finn OJ; Cascio S
Cancer Immunol Res; 2020 Feb; 8(2):167-178. PubMed ID: 31831633
[TBL] [Abstract][Full Text] [Related]
28. The pentacyclic triterpene Lupeol switches M1 macrophages to M2 and ameliorates experimental inflammatory bowel disease.
Zhu Y; Li X; Chen J; Chen T; Shi Z; Lei M; Zhang Y; Bai P; Li Y; Fei X
Int Immunopharmacol; 2016 Jan; 30():74-84. PubMed ID: 26655877
[TBL] [Abstract][Full Text] [Related]
29. Enhancing miR-132 expression by aryl hydrocarbon receptor attenuates tumorigenesis associated with chronic colitis.
Alzahrani AM; Hanieh H; Ibrahim HM; Mohafez O; Shehata T; Bani Ismail M; Alfwuaires M
Int Immunopharmacol; 2017 Nov; 52():342-351. PubMed ID: 29017096
[TBL] [Abstract][Full Text] [Related]
30. Yeast Microcapsule Mediated Natural Products Delivery for Treating Ulcerative Colitis through Anti-Inflammatory and Regulation of Macrophage Polarization.
Feng X; Xie Q; Xu H; Zhang T; Li X; Tian Y; Lan H; Kong L; Zhang Z
ACS Appl Mater Interfaces; 2022 Jul; 14(27):31085-31098. PubMed ID: 35770618
[TBL] [Abstract][Full Text] [Related]
31. Turmeric-derived nanovesicles as novel nanobiologics for targeted therapy of ulcerative colitis.
Gao C; Zhou Y; Chen Z; Li H; Xiao Y; Hao W; Zhu Y; Vong CT; Farag MA; Wang Y; Wang S
Theranostics; 2022; 12(12):5596-5614. PubMed ID: 35910802
[No Abstract] [Full Text] [Related]
32. Difference in the clinical characteristic and prognosis of colitis-associated cancer and sporadic neoplasia in ulcerative colitis patients.
Mutaguchi M; Naganuma M; Sugimoto S; Fukuda T; Nanki K; Mizuno S; Hosoe N; Shimoda M; Ogata H; Iwao Y; Kanai T
Dig Liver Dis; 2019 Sep; 51(9):1257-1264. PubMed ID: 31151895
[TBL] [Abstract][Full Text] [Related]
33. Blocking NFATc3 ameliorates azoxymethane/dextran sulfate sodium induced colitis-associated colorectal cancer in mice via the inhibition of inflammatory responses and epithelial-mesenchymal transition.
Lin Y; Koumba MH; Qu S; Wang D; Lin L
Cell Signal; 2020 Oct; 74():109707. PubMed ID: 32653643
[TBL] [Abstract][Full Text] [Related]
34. The Appendix Orchestrates T-Cell Mediated Immunosurveillance in Colitis-Associated Cancer.
Collard MK; Tourneur-Marsille J; Uzzan M; Albuquerque M; Roy M; Dumay A; Freund JN; Hugot JP; Guedj N; Treton X; Panis Y; Ogier-Denis E
Cell Mol Gastroenterol Hepatol; 2023; 15(3):665-687. PubMed ID: 36332814
[TBL] [Abstract][Full Text] [Related]
35. Single-cell and bulk transcriptomics reveals M2d macrophages as a potential therapeutic strategy for mucosal healing in ulcerative colitis.
Lai W; Xian C; Chen M; Luo D; Zheng J; Zhao S; Li XG
Int Immunopharmacol; 2023 Aug; 121():110509. PubMed ID: 37369160
[TBL] [Abstract][Full Text] [Related]
36. Chemical profile of Xian-He-Cao-Chang-Yan formula and its effects on ulcerative colitis.
Li J; Li M; Ye K; Jiang Q; Wang M; Wen X; Yang J
J Ethnopharmacol; 2021 Mar; 267():113517. PubMed ID: 33164773
[TBL] [Abstract][Full Text] [Related]
37. Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis.
Yaeger R; Paroder V; Bates DDB; Capanu M; Chou J; Tang L; Chatila W; Schultz N; Hersch J; Kelsen D
Clin Colorectal Cancer; 2020 Dec; 19(4):e151-e156. PubMed ID: 32798155
[TBL] [Abstract][Full Text] [Related]
38. Macrophage targeting contributes to the inhibitory effects of embelin on colitis-associated cancer.
Wu T; Dai Y; Wang W; Teng G; Jiao H; Shuai X; Zhang R; Zhao P; Qiao L
Oncotarget; 2016 Apr; 7(15):19548-58. PubMed ID: 26799669
[TBL] [Abstract][Full Text] [Related]
39. TRIM21 Is Decreased in Colitis-associated Cancer and Negatively Regulates Epithelial Carcinogenesis.
Zhou G; Wu H; Lin J; Lin R; Feng B; Liu Z
Inflamm Bowel Dis; 2021 Mar; 27(4):458-468. PubMed ID: 32860065
[TBL] [Abstract][Full Text] [Related]
40. Chronic ulcerative colitis and colorectal cancer.
Rogler G
Cancer Lett; 2014 Apr; 345(2):235-41. PubMed ID: 23941831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
